Ralf von Seelen

OrbusNeich is a major global medical device manufacturer specialized in interventional instruments for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, OrbusNeich sells products to over 70 countries and regions worldwide, and it is also the only PCI balloon manufacturer headquartered in China that ranked among the top 6 players in all major overseas PCI balloon markets including Japan, Europe and the U.S. According to an industry research report, in terms of sales volume of PCI balloons in 2021, OrbusNeich held an over 50% share of the PCI balloon market in Hong Kong, and ranked No. 2 in Japan, No. 4 in Europe, No. 6 in the PRC and No. 6 in the U.S . In addition, in terms of sales volume of PTA balloons in 2021, it ranked No. 3 in Japan and No. 4 in the U.S. In addition to PCI/PTA balloons, it also specializes in coronary stent products and is actively expanding into neuro vascular intervention and structural heart disease areas. OrbusNeich owns more than 180 granted patents globally. Its in-house R&D team has over twenty years of product development experience and has developed proprietary, world leading technologies, including its Scoreflex NC product, the world’s smallest profile non-compliant scoring balloon; its proprietary “drug plus antibody” COMBO dual therapy stent; and its JADE non-compliant peripheral balloon, the first and only non-compliant over-the-wire PTA balloon approved by the FDA that is compatible with all guidewire systems in the U.S. OrbusNeich is listed on the Main Board of The Stock Exchange of Hong Kong Limited (“HKEX”), under the stock code 6929. For more information and news, visit http://www.orbusneich.com/ or follow us on Twitter @OrbusNeich (Last updated on 23rd Dec 2022)